E1B55K-deleted dl1520 could selectively replicate in cancer cells and has been used in clinical trials as an antitumor agent. The mechanism of virus selective replication in cancer cells, including a possible role of p53, is unclear. Studies with established cancer cell lines have demonstrated that some cancer cells are resistant to dl1520 replication, regardless of the p53 status. Hep3B cells supported the E1b-deleted adenoviruses to replicate, whereas Saos2 cells were resistant to viral replication. We applied p53-null Hep3B and Saos2 cells as models to clarify the replication ability of E1B55K-deleted adenoviruses with different expression levels of E1a. We show that lower E1A expression in Saos2 may be the reason for the poor replication in some cancer cells due to the fact that E1a promoter was less activated in Saos2 than in Hep3B. We also demonstrate that the E1B55K protein can increase E1A expression in Saos2 cells for efficient virus replication. In addition, the upstream regions of the E1a promoter have transcriptional activity in Hep3B cells but not in Saos2 cells. The viral E1B55K protein may activate cancer cellular factor(s) that targets the upstream regions of the E1a gene to increase its expression. This is the first study demonstrating that E1B55K protein affects the E1A production levels that is related to cancer selective replication. Our studies have suggested that increase of E1A expression from E1b-deleted adenoviruses may enhance killing cancer cells that otherwise are resistant to viral replication.
Introduction
Tumor selective replication of adenovirus is a promising approach in cancer gene therapy. Two strategies have been applied to genetically alter the adenovirus genome, with the goal of specific viral replication in cancer cells. The first strategy is based on the fact that there are significant similarities between cancer cells and virus-infected cells, in terms of deregulated proliferation and suppressed apoptosis. The major functions of viral E1 genes are dedicated to deregulate cell cycle and inhibit apoptosis. Cancer cells may provide a cellular environment with E1-like factors to allow adenoviruses mutated in E1a or E1b to replicate selectively. We have shown that a mutant adenovirus with an insertion in E1a gene selectively replicates in cancer cells and destroys tumors in vivo.
1 By using viruses with a series of deletions in the E1 regions, viruses with deletions in both E1B55K and E1B19K could still replicate in the human lung cancer A549 cells; only a small fraction of the infected A549 cells underwent E1A-induced apoptosis. 2 The second strategy targets cancer cells by regulation of the essential viral genes involved in replication, using tumor-or tissue-specific promoters that are preferentially active in tumor cells. A number of exogenous promoters that are preferentially active in tumor cells have been used to control the essential E1a and E1b genes in order to generate oncolytic adenoviruses, including the a-fetoprotein (AFP) promoter for replication in hepatocellular carcinomas, [3] [4] [5] [6] the DF3/ MUC1 or other breast cancer-related promoters for targeting breast carcinomas, [7] [8] [9] [10] a Tcf-responsive promoter for colon cancer, 11 and a human tyrosinase promoter for melanoma cells. [12] [13] [14] [15] By using prostate-specific promoters, adenoviral vectors CN706 and CV787 have entered clinical trials for prostate cancer utilizing intraprostatic and intravenous delivery. [16] [17] [18] [19] [20] A combination of CV787 along with radiotherapy significantly increased antitumor efficacy compared to either agent alone. 21 All of these studies intend to enhance cancer selective replication. For more details of adenovirus selective replication and oncolysis, several excellent reviews are available. [22] [23] [24] [25] Adenovirus dl1520 contains an 827-bp deletion in the E1b region and a point mutation that generates a premature stop codon, preventing expression of a truncated form of the E1B55K protein. 26 These mutations render dl1520 incapable of blocking p53-mediated apoptosis. It was hypothesized that dl1520 selectively replicates in and destroys tumor cells carrying mutations of the p53 tumor suppressor gene, as the E1B55K functions are not required in these cells. 27 For this reason, cancer cells with deficient p53 are believed to be permissive for dl1520 replication, whereas cells with wild-type (WT) p53 are not susceptible to dl1520. Some reports have supported this hypothesis, 28, 29 whereas work by several other laboratories found that a variety of tumor cell lines, regardless of their p53 statuses, allows efficient replication of dl1520 and other E1B55K-mutated viruses. [30] [31] [32] Recent reports show that infection with viruses deleted with E1B55K or expressing E1B55K that specifically lacks p53 binding function resulted in accumulation of p53 proteins. 32, 33 The p53 protein accumulated in virus-infected cells is transcriptionally inactive. Expression of MDM and p21 (p53-responsive genes) was not affected by the increased p53. Therefore, E1B55K's role in blocking p53-induced transcription is not required during adenovirus infection.
We are especially interested in determining why some cancer cells are susceptible to dl1520 replication, when others are resistant. Hep3B cells efficiently support dl1520 replication, but Saos2 cells strongly inhibit the virus replication. 30, 31, 34, 35 Both Hep3B 36,37 and Saos2 38,39 are p53 null. We applied Hep3B and Saos2 cells as cancer cell models to investigate virus-cancer selective replication with the goal of improving the efficacy of virotherapy by overcoming tumor resistance to virus replication. In this study, we have applied an adenoviral vector with the strong cytomegalovirus (CMV) promoter replacing the endogenous E1a promoter, and a vector with deletion of the entire E1a original promoter. We have also introduced E2a deletion into dl1520, resulting in dl1520/ÀE2a, which cannot replicate its DNA because of the E2a deletion. We have demonstrated that E1A expression in Saos2 cells was restricted due to E1B55K deletion, and the upstream regions of the E1a promoter have a transcriptional activity that selectively expresses E1a in Hep3B cells but not in Saos2 cells. Therefore, Hep3B cells may contain cellular factor(s) that allow replication of the E1b-deleted dl1520, whereas Saos2 cells may lack such factor. In addition, we observed failing to induce S-phase entry during dl1520 infection in Saos2 cells that may be related with cancer selective replication.
Materials and methods

Cell lines and culture
Human cell lines Hep3B, Saos2, and 293 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Hep3B (ATCC: HB-8064) is a human hepatoma cell line, and Saos2 (ATCC: HTB-85) is a human osteosarcoma cell line. Cell line 293 is a permanent cell line of primary human embryonic kidney cells transformed by sheared human adenovirus type 5 (Ad5) DNA (ATCC, CRL-1573). Hep3B and 293 cells were grown in a-MEM (Gibco, Grand Island, NY), and Saos2 cells were grown in McCoy 5A (Gibco, Grand Island, NY). Both were media-supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 U of penicillin, and 100 g of streptomycin/ml.
Adenoviral vectors
Both adenoviral Adhz51 and Adhz69 vectors contain deletion for E1B55K and the E1a endogenous promoter, which includes the TATA box and transcription start site. The strong CMV promoter was inserted in Adhz69 in the E1a endogenous promoter place. Therefore, Adhz51 does not contain any known promoter for the E1a ORF, and Adhz69 contains the strong CMV promoter for controlling E1a ORF (Figure 1a ). dl1520 with deletion for E1B55K was originally reported by Barker and Berk 26 and has extensively been used in basic and clinical studies for selective replication in cancer cells and oncolysis. AdCMV/lacZ (AdlacZ) is an adenovirus vector with E1 deleted and with the lacZ gene as a reporter. 40 In this study, we created dl1520/ÀE2a by deletion of the E2a gene from dl1520, using the E1-and E2a-deleted vector system that we previously reported (Figure 4a) . 41, 42 The E2a gene is essential for viral DNA replication. All of the vectors created and used in this study are based on the backbone of adenovirus type 5 (Adwt). Adwt was obtained from ATCC and used as a control in this study.
Western blot analysis
Hep3B cells and Saos2 cells were infected with various viruses at a multiplicity of infection (MOI). Cells were harvested at 24 h after infection and lysed in a RIPA lysis buffer (50 mM Tris HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) with a protease inhibitor cocktail containing 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), pepstatin A, transepoxysuccinyl-lleucylamido(4-guanidino)butane(E-64), bestatin, leupeptin, and aprotinin (10 ml/10 6 cells; Sigma, St Louis, MO) for 30 min. Cell lysates were centrifuged, and protein concentration was determined by BIO-RAD DC protein assay (BIO-RAD, Hercules, CA). Equal amounts (30 mg) of cellular protein were electrophoresed in SDS-polyacrylamide gels and transferred to a Hybond-PVDP membrane (Amersham, Arlington Heights, IL). The membrane was incubated with the primary antibodies diluted in phosphate-buffered saline (PBS) containing 0.5% BSA and 0.1% Tween-20. Purified anti-Ad5 EIA monoclonal antibody (BD Biosciences, San Diego, CA), p53 antibody Ab-14 (clone ICA.9, Lab Vision, Fremont CA), anti-E1B-55K monoclonal antibody (2A6) 43 (generous gift from AJ Levine, Rockefeller University) was diluted 1:10. Binding of the primary antibody was detected using a secondary antibody, antimouse or antirabbit immunoglobulin (Ig) conjugated to horseradish peroxidase (Amersham, Arlington Heights, IL). ECL reagents were used to detect the signals, according to the manufacturer's instructions (Amersham, Arlington Heights, IL). A549 cells (p53 positive) were used in the experiment to determine p53 expression after infection with various viruses at an MOI of 10 because both Hep3B and Saos2 cells are p53 negative.
X-gal staining for b-galactosidase expression The infective efficiency of adenovirus to Hep3B and Saos2 cells were monitored by assaying lacZ gene expression from the AdlacZ vector using X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranosied) staining. At 1 day after infection with AdlacZ, Hep3B and Saos2 cells were fixed with 0.2% glutaraldehyde and 2% formaldehyde in cold PBS for 5 min at room temperature. This was then incubated at 371C overnight with 0.1% Xgal, which is freshly made by adding 1 ml of 4% X-gal in DMF (stocked at À201C) into 40 ml of a solution of 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , and 2 mM MgCl 2 in PBS (stocked in dark). The staining cells were observed in an Olympus E600 microscope equipped with a SPOT RT digital camera.
Assessments of cytopathic effect (CPE) and viral replication Cells were seeded in six-well plates with appropriate medium at a density of 1 Â 10 6 cells/well, and cells were infected with Adwt, dl1520, Adhz51, Adhz69, or AdlacZ at an MOI of 1 and 10. The medium was replaced with fresh medium 3 h after infection. The cells were observed for CPE. Total cells and culture supernatant were harvested at 48 h postinfection. The cell lysate was prepared with three cycles of freezing and thawing. The titer of adenovirus was evaluated by standard plaqueforming assay with 293 cells in six-well plates, as described previously. 42, 44 Viral DNA assay To compare viral DNA within infected cells, Hep3B and Saos2 cells were divided into 10-cm dishes at 2 Â 10 6 /dish. The following day, the cells were infected with dl1520/ÀE2a at an MOI of 100 for 3 h, as aforementioned. The cells were collected at 24 h postinfection. Subsequently, total DNA was isolated from the infected cells for Southern blot analysis. The positive control was dl1520/ÀE2a DNA amplified in the E2a complementing E2T cells. 41 DNA samples (5 mg each) after digestion with PstI were added to 0.8% agarose gel for electrophoresis and transblotted to a Hybond-N þ membrane (Amersham Pharmacia Biotech, YA3609, Arlington Heights, IL). To prepare the probe for the Southern blot, 100 ng of pBHGE3 45 DNA was also digested with PstI, denatured for 5 min in boiling water, and then cooled on ice for 5 min. The reaction buffer, labeling reagent, and crosslinker were added to the DNA, following the protocol of the AlkPhos DIRECT kit (Amersham Pharmacia Biotech, RPN 3690). The reaction was carried out at 371C for 30 min. Prehybridization was performed for 15 min at 551C, with 0.125 ml of hybridization buffer/cm 2 . The probe was added to the hybridization buffer at 10 ng/ml, and hybridization was performed overnight at 551C with gentle agitation. For detection, the blot was drained after hybridization, and CDP-Start detection reagent was added onto the blot membrane at 30 ml/cm 2 and kept at room temperature for 5 min. Then, the membrane was exposed to film for about 1 min before development.
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry. At the indicated time points after mock, Adwt, and dl1520 infection at an MOI of 1, approximately 10 6 cells were collected by centrifugation, washed once with cold PBS, and fixed with 1 ml of 70% cold ethanol at À201C for at least 45 min, washed with PBS again, and treated with 1 ml propidium iodide (PI) staining solution (1 Â PBS, 1 mg/ml RNase A DNase-free, 1 mg/ml propidium iodide, Sigma) at room temperature for 30 min. Cell cycle analysis was carried out with a fluorescence-activated cell sorter ((FACS) Becton Dickinson, Franklin Lakes, NJ) acquiring 10 000 events.
Results
Saos2 and Hep3B cells are equally infected by adenoviruses
In both Adhz51 and Adhz69, the endogenous E1a promoter and the E1B55K ORF region have been deleted (Figure 1a ). With the deletion in E1B55K region, Adhz51 and Adhz69 are not able to produce E1B55K protein. To assess expression of E1B55K, we infected A549 cells with Adhz51 and Adhz69 at an MOI of 10. Cell extracts at 24 h.p.i. (hour postinfection) were prepared for Western blot analysis. Adwt and dl1520 were also used as positive and negative controls for E1B55K expression. Only Adwt expressed E1B55K protein. Adhz51 and Adhz69 could not produce any E1B55K protein because of the deletion as the negative control dl1520 (Figure 1b) . As the E1B55K gene in Adhz51 and Adhz69 is only partially deleted, the mutated E1B55K protein may be produced but cannot be detected with the monoclonal antibody used to determine E1B55K protein. The major known function of E1B55K is to bind and degrade p53 protein; infection with a viral mutant lacking E1B55K results in an increase of p53 protein levels in cells. 46 To determine if there is a loss of p53 degradation function due to the E1B55K deletion in Adhz51 and Adhz69, we infected A549 cells (wild-type p53). Infection with Adhz51 and Adhz69 increased p53 protein in A549 cells as did E1B55K-deleted dl1520, but barely detected in the cells infected with Adwt (Figure 1b) . Thus, Adhz51 and Adhz69 were confirmed to have lost the expression of E1B55K and its function.
In order to compare the responses of Saos2 and Hep3B cells to virus infection, it is important to have Saos2 and Hep3B cells equally infected. We used the replication incompetent AdlacZ as a report vector to infect Saos2 and Hep3B cells at an MOI of 1, 10, or 100 plaque-forming units (PFUs). The cells were fixed and analyzed for b-galactosidase activity at 24 h.p.i. Figure 1c shows the overview of the X-gal-stained cells. This result showed that there was no significant difference in the fraction of b-galactosidase-positive cells between Hep3B and Saos2 infected at the same MOI, and almost all the cells were infected with 10 PFU/cell (Figure 1c ). These results indicated that Saos2 and Hep3B cells were equally and efficiently infected by adenoviruses in this experiment setting; this conclusion was further verified by Southern blot experiment in Figure 5 .
E1A expression levels affect the CPE of E1B55K-deleted adenoviruses in Saos2 cells
In order to determine whether the E1A expression level is an important factor related to the different CPE between the two cancer cell lines, Hep3B and Saos2 cells were infected with Adhz51 without the endogenous E1a promoter and Adhz69 with the CMV promoter for E1a gene, Adwt and dl1520 at an MOI of 0, 1, and 10. At 2 days after infection, cells were observed for CPE that were characterized by unattached and rounded-up cells. Similar to the data reported by Steegenga et al., 34 CPE were observed in Hep3B cancer cells infected with dl1520 but not in the Saos2 cells (Figure 2) . In fact, all the viruses can destroy Hep3B cells. As expected, Adhz51 without any known promoter to control E1a did not cause significant CPE in Saos2 cells. However, Adhz69 with the strong CMV promoter controlling E1a did induce the CPE in Saos2 cells (Figure 2) , suggesting that overexpression of E1A from Adhz69 appeared to compensate for the lost function of E1B55K in this cell line. Our data indicated that E1A expression level is a key factor affecting the CPE ability of E1B55K-deleted adenoviruses in Saos2 cells.
High level of E1A overcome the restriction of E1B55K-deleted virus replication in Saos2 cells
To further confirm the results of CPE, we compared the titers of viruses produced in Hep3B and Saos2 cells. We used Adwt, dl1520, Adhz51, and Adhz69 to infect these two cell lines at an MOI of 1. The titers of all four tested viruses reached 10 7-8 PFU in Hep3B cells at day 2 postinfection, with no significant difference (Figure 3a) . The titers of dl1520 and Adhz51 produced in Saos2 cells were about 10 5 PFU, 1000-fold lower than that in Hep3B cells. The titers of dl1520 and Adhz51 in Saos2 cells were only slightly higher than the viruses added into the cell cultures for infection, as indicated by the dashed line in Figure 3a , suggesting that replication of dl1520 and Adhz51 was strongly restricted in Saos2 cells. However, the titers of Adwt and Adhz69 produced in Saos2 cells were comparable with the titer of the same viruses produced in Hep3B cells. These results demonstrate that viruses with deletion of E1B55K (dl1520) or deletions of both the E1a promoter and the E1B55K (Adhz51) could still efficiently replicate in Hep3B cells and cause CPE (Figure 2 ), but they have lost the ability to replicate in Saos2 cells. This seems to be in agreement with the concept that E1B55K is required for virus replication in Saos2 cells but not in Hep3B cells. 34 On the other hand, application of the strong CMV promoter to control E1A expression could lead to replication (Figure 3a ) and CPE induction (Figure 2 ) of the E1B55K-deleted Adhz69 in Saos2 cells. These results of viral replications and CPE together suggest that the E1B55K-deleted viruses (dl1520 and Adhz51) can efficiently replicate in Hep3B cells but not in Saos2, and that viruses (Adhz69) with the E1a ORF controlled by the strong CMV promoter can overcome the restriction of viral replication of the E1B55K-deleted viruses in some cancer cells, such as Saos2 cells.
Selective
, and Adhz69, all contain deletion of E1B55K region. Adwt and dl1520 contain the endogenous E1a promoter. The E1a promoter and its transcription start site have been deleted in Adhz51 and Adhz69 vectors. In Adhz69, the CMV promoter has been added to control E1A expression. Thus, Adhz51 is a mutant without any known promoter controlling the E1a gene and Adhz69 has the E1a ORF controlled by the strong CMV promoter. In the above experiment, we have shown that Adhz51 with deletions of the E1B55K region and the entire E1a promoter could still replicate in Hep3B cells but not in Saos2 cells, and the CMV promoter in Adhz69 allowed the E1B55K-deleted virus to replicate and cause CPE in both Hep3B and Saos2 cells. These results suggest that E1A levels are involved in virus selective replication in some cancer cells (Figures 2 and 3) . In order to verify the levels of E1A protein from Adhz51 and Adhz69, Western blot analysis was carried out using mouse monoclonal anti-E1A antibody. We observed that E1A proteins were expressed at higher levels in Hep3B cells than in Saos2 cells, after infection with Adwt, dl1520, or Adhz51 (Figure 3b) . In Saos2 cells, the E1A expression from dl1520 is lower than that from Adwt, although both Adwt and dl1520 viruses contain the same endogenous E1a promoter and can produce E1A proteins at similar levels in Hep3B cells. Comparing E1A proteins expressed from Adwt and dl1520 in Hep3B and Saos2 cells, we believe that E1B55K protein is required for efficient expression of E1A in Saos2 cells, but this requirement is not needed in Hep3B cells (Figure 3b) .
Deletion of the entire E1a promoter in Adhz51 further inhibited E1A expression in Saos2 cells; E1A proteins were barely observed in the lane of dl1520-Saos2 in Figure 3b . E1A products from Adhz51 in Hep3B cells also decreased, but still produced a fair amount of E1A proteins. These results may explain why the E1a-promoterless Adhz51 could still replicate in Hep3B cells, but the replication was inhibited in Saos2 cells (Figure 3a) . E1A expression from Adhz51 in Hep3B cells suggested that the upstream regions (the ITR region and the viral DNA packaging site, C) of the E1a gene have transcriptional activity for E1A expression (Figure 1) . Therefore, even in the case where the entire E1a promoter has been removed in Adhz51, the E1a upstream regions could still transcribe E1a ORF and result in production of E1A proteins in Hep3B cells. It was reported previously that deletion of the E1a promoter did not decrease the efficiency of virus replication in HeLa cells. 47, 48 Our study, for the first time, has demonstrated that the transcriptional activity of the E1a upstream regions is dependent on cell type as the E1A production from Adhz51 is significantly limited in Saos2 cells but not in Hep3B cells (Figure 3) .
Using the universal and strong CMV promoter to drive E1a ORF, Adhz69 overcame the limitation on E1A expression caused by deletion of the E1a promoter and E1B55K, and resulted in the highest levels of E1A expression in both Saos2 and Hep3B cells (Figure 3b ). The increased E1A proteins allowed the E1B55K-deleted Adhz69 to replicate in Saos2 cells. Otherwise, the replication would be inhibited in this type of cell, as shown in infections with dl1520 and Adhz51 (Figure 3b) . Therefore, the repressed E1A expression due to the E1B55K deletion may account for the inefficient replication of dl1520 and Adhz51 in Saos2 cells.
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Cancer Gene Therapy E2a deletion in dl1520 restrains virus replication Based on the above experiments, we already know that replication of dl1520 and Adhz51 is significantly restricted in Saos2 cells, probably due to lower levels of E1A expression from the two E1B55K-deleted viruses in Saos2 cells. However, replication itself could produce more viral DNA and lead to higher E1A production. Western blot analysis at 24 h postinfection might not reflect the initial E1A expression. Therefore, we are not sure whether the lower E1A is the cause or the consequence of restricted viral replication. In this study, we created a new virus dl1520/ÀE2a in which the whole E2a gene was also deleted from dl1520. The dl1520/ÀE2a vector is identical to dl1520, except for the E2a deletion in the viral genome ( Figure 4a ). As the E2a gene is essential for viral DNA synthesis, the d11520/ÀE2a virus should be replicationincompetent. To confirm this, we infected both Saos2 and Hep3B cells with dl1520 and dl1520/ÀE2a. Figure 4b showed that dl1520 caused complete CPE in Hep3B cells after infection at an MOI of 10 for 2 days, whereas dl1520/ÀE2a could not induce any CPE in both Hep3B and Saso2 cells. Using the E2a-deleted vector system, we were able to clarify the role of E1B55K on E1A expression in a condition excluding virus replication.
The E1a promoter was activated in Hep3B cells but restricted in Saos2 cells
To determine the E1a promoter activity in Hep3B and Saos2 cells, we infected these cells with dl1520 or dl1520/ ÀE2a at an MOI of 1, 10, and 100. Total proteins were isolated from cells 24 h after infection, for Western blot analysis of E1A proteins produced in Hep3B and Saos2 cells. The E1A proteins produced by dl1520 was much greater than that by dl1520/ÀE2a in both Hep3B and Saos2 cells, regardless of the MOI used for the infection (Figure 5a ), suggesting that dl1520 DNA replication did increase E1A expression. We further compared E1A protein levels in dl1520/ÀE2a-infected Hep3B and Saos2 cells. dl1520/ÀE2a produced E1A proteins about 10-fold higher in Hep3B cells than that in Saos2 cells ( Figure 5a ). As dl1520/ÀE2a cannot replicate in both Hep3B and Saos2 cells, E1A proteins produced by dl1520/ÀE2a are the direct products of the viral DNA from transduction. The results clearly indicate that the endogenous E1a promoter in the E1B55K-deleted virus is more activated in Hep3B cells than that in Saos2 cells. Unlike the data reported by Steegenga, 34 we showed that Hep3B and Saos2 cells could be equally infected by adenoviruses (Figure 1c ). This conclusion was further verified by comparing the viral DNA uptake between the two cell lines after dl1520/ÀE2a infection. Hep3B and Saos2 cells were infected with dl1520/ÀE2a at an MOI of 100. A day after infection, total DNA was isolated from the infected cells for Southern blot analysis to determine the relative amount of viral DNA in Hep3B and Saos2 cells. With equal loading of 5 mg DNA samples in each lane, the Southern blot demonstrated that the dl1520/ ÀE2a viral DNA was equally transduced into Hep3B and Saos2 cells (Figure 5b ). The positive control is dl1520/ ÀE2a DNA amplified in the E2a complementing E2T cells. 41 Thus, we excluded the possibility that infectivity could be the reason to explain the differing ability of E1A expression and dl1520 replication between the two cell types.
Adenoviruses-induced cell cycle changes in Hep3B and Saos2 cells
The above experiments showed that the E1a promoter in adenovirus is more activated in Hep3B cells than in Saos2 cells, and E1B55K can enhance E1A expression (Figures 3  and 5 ). E1A proteins interact with several key cellular Figure 5 (a) Western analysis of E1A proteins produced in Hep3B and Saos2 cells infected with dl1520 and dl1520/ÀE2a. Total proteins were isolated from cells 24 h.p.i. with dl1520 or dl1520/ÀE2a at an MOI of 1, 10, or 100. dl1520 infection resulted in higher levels of E1A expression in Hep3B cells than that in Saos2 cells. Infection with dl1520/ÀE2a also produced higher E1A proteins in Hep3B cells. However, E1A proteins produced by dl1520/ÀE2a in both Hep3B and Saos2 cells are much lower than that produced in dl1520-infected cells. As dl1520/ÀE2a cannot replicate in infected cells, the lower level expression of E1A in Saos2 cells should be due to the repressed activity of the E1a promoter in Saos2 cells. b-Actin was used as a control to demonstrate an equal loading and transfer. (b) Adenovirus dl1520/ÀE2a DNA transduced into Saos2 and Hep3B cells. Southern blot method has been used to determine the dl1520/ÀE2a viral DNA within Saos2 and Hep3B cells. The positive control is dl1520/ÀE2a DNA amplified in E2a complementing E2T cells. The dl1520/ÀE2a DNA is approximately equal in Saos2 and Hep3B cells after infection with dl1520/ÀE2a.
proteins, including pRb and p300, to reprogram cellular gene expression and cell cycle regulation. 49 E1A can force host cells into S phase to provide an optimal cellular environment for viral replication. Thus, we further investigate whether the cell cycle progression is correlated with cancer selective replication of dl1520. Hep3B and Saos2 cancer cells were infected with AdlacZ (control), Adwt, or dl1520, at an MOI of 1. After infection, cells were collected at different time points and stained with PI for flow cytometry analysis. Hep3B and Saos2 cells infected with the control vector AdlacZ did not show significant cell cycle changes (Figure 6 ). Adwt infection induced both Hep3B and Saos2 cells to enter S phase peaked at 20 h.p.i., and then cells further moved into G2/M phase at 28-32 h, although the total percentages of Adwt-infected Saos2 cells in S and G2/M were not as high as the Adwt-infected Hep3B cells. dl1520 infection also induced Hep3B cell cycle changes in a similar manner as Adwt-infected Hep3B cells. In contrast with the dl1520-infected Hep3B cells, the infection of dl1520 did not cause significant alteration in the Saos2 cell cycle profile ( Figure 6 ). Thus, dl1520 could efficiently induce cell cycle progression in infected Hep3B cells, but not in Saos2 cells. Adwt infection, on the other hand, could drive cell cycle progression in both Hep3B and Saos2 cells. It is possible that the poor replication of dl1520 in Saos2 cells may be associated with the lack of cell cycle progression as a consequence of lower E1A expression in dl1520-infected Saos2 cells.
Discussion dl1520 is an E1B55K-deleted adenovirus that has been used in clinical trials as an antitumor agent. Clinical trials have shown that dl1520 as a single anticancer agent cannot efficiently inhibit tumor growth. [50] [51] [52] One possible explanation for the limited efficacy of dl1520 in the clinical treatments is that some cancer cells within tumors may be resistant to dl1520 replication, just as some established cancer cell lines are resistant to dl1520 replication. Cancer cells that are resistant to viral replication will survive the treatment and continue its growth. A major challenge in virus-mediated oncolytic therapy is to increase the efficiency of virus selective replication, so that the therapeutic viruses can destroy all cancer cells, including those that are otherwise resistant to virus replication. On the basis of the observation that the E1B55K protein is able to bind to and inactivate p53, dl1520 is proposed to replicate in and kill p53-deficient cells. However, the mechanism of tumor selectivity, including a possible role of p53 in this regard, is still not well known.
Recent studies showed that E1B55K protein is not required to block p53-mediated transcriptional activity during adenovirus infection. 32 This result was confirmed by other laboratory. 33 These two independent studies applied an E1B55K mutant R239A (ONYX-053), which produces a mutated E1B55K protein that specifically lacks the binding ability with p53. These studies demonstrated that loss of E1B55K function in inactivation of p53 or lack of E1B55K protein in dl1520 infection leads to accumulation of p53 in infected cells, as expected. However, increased p53 proteins in cells infected with the E1B55K-mutated viruses did not induce expression of p53-responsive genes, p21 and MDM, suggesting that p53 protein is inactivated in the absence of E1B55K. Other viral proteins may also be involved in blocking p53 transcriptional activity. In addition, further studies showed that the viral RNA export functions of E1B55K is involved in viral replication and dl1520-sensitive tumor cells may provide with altered mechanisms of factors with E1B55K functions for RNA export. 33 Heat shock response rescues late viral RNA export and renders refractory tumor cells permissive to dl1520. 53 A specific question that we investigated in this study is how dl1520 can efficiently replicate in some cancer cells, but its replication is limited in other cancer cells. In order to study this question in a cellular environment that excludes effect of p53 factor, we used p53-null Hep3B and Saos2 cells as models. Adenovirus dl1520 could efficiently replicate in Hep3B cells, but not in Saso2 cells. 30, 31, 34, 35 We showed that dl1520 produced much higher levels of E1A proteins in Hep3B cells than that in Saos2 cells (Figure 3) . The repression of E1A production from dl1520 in Saos2 cells may lead to limited viral DNA replication. However, the limited E1A expression could be the cause or the consequence of inhibited replication of dl1520 in Saos2 cells, as lower numbers of viral genomic DNA could result in lower E1A production. To clarify this question, we introduced E2a deletion into dl1520. With deletion of the E2a gene, dl1520/ÀE2a cannot replicate in both Hep3B and Saos2 cells. Using the dl1520/ÀE2a vector, we demonstrated that the level of E1A proteins was 10-fold higher in Hep3B than that in Saos2 cells ( Figure 5 ). Thus, we clearly show that E1A expression level is variable depending on cell types. We do not know the exact reasons as to why the endogenous E1a promoter is more activated in Hep3B cells than in Saos2 cells (Figures 3 and 5) . The primary E1A translation products undergo extensive phosphorylation that is mediated, at least in part, by cyclin-dependent kinases 54 and mitogenactivated protein kinase. 55 It is also possible that some cellular factors may be involved in E1a gene expression.
We also show that lack of E1B55K in dl1520 results in further decrease of E1A expression in Saos2 cells (Figure 3 ). The E1B55K protein may be required for the high level of E1A expression in Saos2 cells for efficient virus replication. However, the E1A expression from dl1520 is not significantly inhibited in Hep3B cells compared with Saos2 cells, suggesting that E1B55K is not required for expression of high levels of E1A in Hep3B cells. We reason that some cancer cellular factors in Hep3B cells but lacking in Saos2 cells may contribute to the increased E1A expression in Hep3B cells in the absence of E1B55K.
Deletion of the entire E1a promoter in Adhz51 almost totally eliminated E1A expression in Saos2 cells, but the E1a-promoterless vector could still produce E1A proteins in Hep3B cells (Figure 3) . The viral DNA regions in the upstream of the E1a promoter are the inverted terminal repeat (ITR, 1-103 bp) located on the left end of the adenoviral genome, and the viral DNA package region 194-358 bp) located between the ITR and the E1a promoter (Figure 1 ). This study has demonstrated that the upstream regions of the E1a promoter have transcriptional activity in Hep3B cells but not in Saos2 cells. Adhz51, with expression of E1A at 10% of the normal level (compared with Adwt-infected Hep3B cells, Figure 3b ), still can efficiently replicate in Hep3B cells (Figure 3a) . The E1A production from Adhz51 is almost completely blocked in Saos2 cells, resulting in poor virus replication. As the transcription function of the upstream regions of the E1a promoter is only activated in Hep3B cells, the upstream regions may also account for higher E1A expression in Hep3B cells (Figure 3) .
To further study the effect of E1A expression levels on viral replication, we applied the CMV promoter to drive E1a ORF in Adhz69 (Figure 1) . The CMV promoter led to the highest level expression of E1A proteins in both Saos2 and Hep3B cells (Figure 3b ). The increased E1A proteins allowed the E1B55K-deleted Adhz69 to replicate in both Saos2 and Hep3B cells, whereas dl1520 and Adhz51 could only efficiently replicate in Hep3B cells (Figure 3a) . Therefore, increased E1A expression overcomes the limitation of virus replication in Saos2 cells caused by deletion of E1B55K. Small DNA viruses, such as adenovirus and human papillomavirus, encode proteins that promote cells to enter the S phase necessary for viral DNA synthesis. The major function of the E1A proteins is to control host cell cycle and create an optimal environment for viral replication. The data presented in this study suggest that higher levels of E1A expressed in dl1520-infected Hep3B cells may enhance cell cycle progression and strengthen viral replication ( Figure 6 ). Taken together, our study has demonstrated that E1B55K protein can increase E1A expression, and the upstream regions of the E1a promoter have transcriptional activity in Hep3B cells but not in Saos2 cells. E1B55K probably target the upstream regions of the E1a gene via activation of cellular factor(s) (Figure 7) . The cellular factors (such as cyclin E and E2F) may be already highly activated in many cancer cells, including Hep3B, so that the E1B55K functions are not required for E1A expression and viral replication in these cells. However, E1B55K is required for viral replication in normal and other cancer cells (such as Saos2) that may lack the cellular factor activity. The E1B55K may have a role in cell cycle regulation. The results obtained in this study provide an additional explanation as to why dl1520 can replicate in many cancer cells, whereas replication is restricted in normal and other cancer cells. Our studies have suggested that genetically engineered adenoviruses with deletion of E1b and selective overexpression of E1A may enhance killing cancer cells that otherwise are resistant to dl1520 replication.
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